Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus.
Xiujuan ChangShumin YuJianzhi PangWei ZhangHuifang KongJiagan HuangGuojie ZhangHuixin ZhangYueyue GuYan ChenBin YangJingping LiuZhen ZengPublished in: Journal of hepatocellular carcinoma (2023)
The lenvatinib combined with at least 3 cycles of anti-PD-1 was efficacy and safe for u-HCC patients infected with HBV. Especially, patients with PVTI or EHS combined with CPB may benefit most from the combination therapy.